Short introductionabout us: immunitoAI is a lifesciences (biotech) startup that leverages AI to revolutionize antibodydiscovery. Positioned to scale globally, our full stack-platform will predictthe best therapeutic antibody candidates, saving time by 60% and money by 50%,and increasing efficiency by 2X. The problem we are solving and how: Antibodies are capable of providing target specific therapies as well as highlyspecific diagnostics but the major drawback is that it takes months to years to discover new antibodies that have the specificity and sensitivity required forthese purposes. In order to tackle this problem, we are building a platformthat uses AI assisted screening and discovery at the core of its technology.The first version of our AI will identify antibodies with higher specificity& sensitivity, & reduced immunogenicity. Later, the AI will be able tosuggest novel antibody candidates that are suited for therapeutics. Our bigvision is to be a full-stack antibody therapeutics company that willmanufacture novel therapeutic antibodies, designed and discov
Momentum is derived from funding recency, velocity, round count and scale. Risk reflects registry status and funding staleness.
immunitoAI is a TechBio company developing AI-generated novel antibody therapeutics with pre-defined drug properties.
Computer and related activities
Source: Ministry of Corporate Affairs company master (open data). Capital figures are as-of the 2021 registry snapshot, not live.
Extracted from Immunitoai Private Limited's own website, fetched Jul 2026. Verification badges reflect format/MX checks, not endorsement.